Question 1

Purpose of the Analysis

Accepted Answer

To identify if the tumor contains mutations in the KRAS or NRAS genes. To predict the response of colorectal cancer patients to targeted anti-EGFR therapies. To avoid using treatments that may be ineffective based on the tumor's genetic profile.

Question 2

Target Groups

Accepted Answer

Patients with metastatic colorectal cancer (mCRC). Patients being considered for targeted therapies such as Cetuximab or Panitumumab. Oncology cases requiring precise molecular characterization of the tumor.

Question 3

Understanding the Results

Accepted Answer

Wild-type: Indicates no mutation found; suggests a likely positive response to anti-EGFR therapy. Mutated: Indicates a mutation is present; suggests anti-EGFR therapy will likely be ineffective. The final therapeutic decision is made by the oncologist based on the genomic report.

Precision Targeted Cancer Therapy Guidance - RAS Mutation Analysis (KRAS/NRAS)